List view / Grid view

News

Efficacy and safety data for ZOSTAVAX®

2 April 2012 | By Merck

Merck announced that data from the pivotal Phase III study with ZOSTAVAX® in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases...